CEREBRAL THERAPEUTICS
Cerebral Therapeutics is a clinical-stage pharmaceutical company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy.
CEREBRAL THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2010-01-01
Address:
Aurora, Colorado, United States
Country:
United States
Website Url:
http://www.cerebraltherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
303 547 3448
Total Funding:
85.8 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Content Delivery Network Euro Microsoft Exchange Online Office 365 Mail Google Apps For Business
Similar Organizations
Ablaze Pharmaceuticals
Ablaze Pharmaceuticals is a clinical-stage pharmaceutical company.
Acasti Pharma
Acasti Pharma is an emerging biopharmaceutical company.
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Arkuda Therapeutics
Arkuda Therapeutics is a pharmaceutical company.
Avalo Therapeutics
Avalo Therapeutics is a clinical-stage biopharmaceutical company.
Sio Gene Therapies
Sio Gene Therapies is a clinical-stage biopharmaceutical company.
Caladrius Biosciences
Caladrius Biosciences is a clinical-stage biopharmaceutical company.
Calimmune
Calimmune is a clinical-stage gene therapy company.
Circadian Therapeutics
Circadian Therapeutics is a Pharmaceutical company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
CVSPharmacy
CVSPharmacy is a retail pharmacy.
Destiny Pharma
Destiny Pharma Ltd., a clinical stage pharmaceutical company
Helsinn Birex Pharmaceuticals
Helsinn is a world class cancer care company.
Heron Therapeutics
Heron Therapeutics is a biotechnology firm specializing in polymer-based pharmaceuticals.
Humanetics Corporation
clinical stage pharmaceutical company.
Leap Therapeutics
Leap Therapeutics is a clinical-stage biopharmaceutical company.
MediPrint Ophthalmics
MediPrint Ophthalmics is a clinical stage eye care pharmaceutical company.
Osmotica Pharmaceutical
Osmotica Pharmaceutical is a global specialty pharmaceutical company.
Qilu Pharmaceutical
Qilu Pharmaceutical is a large and comprehensive pharmaceutical company
Novelion Therapeutics
Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company
SAB Biotherapeutics
SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.
Saol Therapeutics
Saol Therapeutics is a biotech pharmaceutical company.
Soleno Therapeutics
Soleno Therapeutics is a clinical-stage biopharmaceutical company.
Summit Therapeutics
Summit Therapeutics is a clinical-stage drug discovery and development company.
Verva Pharmaceuticals
Verva Pharmaceuticals is a clinical-stage pharmaceutical company.
Zentera Therapeutics
Zentera Therapeutics is a biopharmaceutical company.
Current Advisors List
Board_member
Board_observer
Board_member
2022-06-01
Board_member
2022-06-01
Current Employees Featured
Daniel J. Abrams Co-Founder & CEO @ Cerebral Therapeutics
Co-Founder & CEO
Guy Anthony CFO @ Cerebral Therapeutics
CFO
2021-05-01
Founder
Investors List
Vivo Capital
Vivo Capital investment in Series C - Cerebral Therapeutics
RA Capital Management
RA Capital Management investment in Series C - Cerebral Therapeutics
Granite Point Capital
Granite Point Capital investment in Series C - Cerebral Therapeutics
Lynx1 Capital Management
Lynx1 Capital Management investment in Series C - Cerebral Therapeutics
Perceptive Advisors
Perceptive Advisors investment in Series C - Cerebral Therapeutics
Perceptive Advisors
Perceptive Advisors investment in Series B - Cerebral Therapeutics
Granite Point Capital
Granite Point Capital investment in Series B - Cerebral Therapeutics
RA Capital Management
RA Capital Management investment in Series B - Cerebral Therapeutics
Vivo Capital
Vivo Capital investment in Series B - Cerebral Therapeutics
Granite Point Capital
Granite Point Capital investment in Series A - Cerebral Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-08-03 | Cerebral Therapeutics, Inc. Names Guy Anthony as Chief Financial Officer |
Official Site Inspections
http://www.cerebraltherapeutics.com Semrush global rank: 5.6 M Semrush visits lastest month: 1.51 K
- Host name: 198.49.23.144
- IP address: 198.49.23.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Cerebral Therapeutics"
Cerebral Therapeutics - Crunchbase Company Profile
Cerebral Therapeutics is a clinical-stage pharmaceutical company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy.See details»
Cerebral Therapeutics Company Profile | Management and
Cerebral Therapeutics Profile and History . Cerebral Therapeutics, LLC (www.cerebraltherapeutics.com) is a privately-held company founded with the goal of …See details»
Cerebral Therapeutics - Craft
Apr 16, 2019 Cerebral Therapeutics has 1 employees across 2 locations and $10.8 m in total funding,. See insights on Cerebral Therapeutics including office locations, competitors, …See details»
Cerebral Therapeutics - PitchBook
Clinical Trials - Phase 2. 1. Later Stage VC (Series A) 08-Mar-2019. $11M. $11M. Completed. Clinical Trials - Phase 2. To view Cerebral Therapeutics’s complete valuation and funding …See details»
Cerebral Therapeutics - Overview, News & Similar companies
Jun 27, 2022 Cerebral Therapeutics, LLC (www.cerebraltherapeutics.com) is a privately-held company founded with the goal of addressing the well-recognized limit ations of existing …See details»
Cerebral Therapeutics Names Julie Foster as Chief Operating Officer
Jan 25, 2023 Julie Foster Chief Operating Officer P: 303-547-3448 E: info@cerebraltherapeutics.com Contacts Julie Foster Chief Operating Officer P: 303-547-3448 …See details»
Cerebral Therapeutics, Inc. Secures $40 Million Series C Financing
Jun 28, 2022 John Foster President & Chief Operating Officer P: 303-547-3448 E: info@cerebraltherapeutics.com. Contacts. John Foster President & Chief Operating Officer P: …See details»
Cerebral Therapeutics Raises Series A Financing to Advance …
AURORA, Colo., June 20, 2018 /PRNewswire/ -- Cerebral Therapeutics, Inc., a clinical-stage company focused on implanted drug-device combination therapies to improve the lives of …See details»
Cerebral Therapeutics Strengthens Clinical Development …
Apr 16, 2019 For more information please visit www.cerebraltherapeutics.com. For Investors: Tiberend Strategic Advisors, Inc. Tirth Patel 212-375-2694 [email protected] SOURCE …See details»
Cerebral Therapeutics Names John Foster as President and Chief ...
Sep 24, 2019 For more information, please visit www.cerebraltherapeutics.com. For Investors: Tiberend Strategic Advisors, Inc. Tirth Patel 212-375-2694 [email protected] SOURCE …See details»
Cerebral Therapeutics Appoints Stephen J. Farr as Chairman and …
Nov 10, 2020 John Foster President & Chief Operating Officer P: 303-547-3448 E: info@cerebraltherapeutics.com. Contacts. John Foster President & Chief Operating Officer P: …See details»
Cerebral Therapeutics, Inc. Secures $40 Million Series C Financing
Jun 28, 2022 For more information visit www.cerebraltherapeutics.com. About Refractory Epilepsy. Epilepsy is the fourth most common neurological condition globally. Approximately …See details»
Cerebral Therapeutics, Inc. Secures $40 Million Series C Financing
Jul 21, 2022 Cerebral Therapeutics, a clinical-stage pharmaceutical company pioneering therapies for neurological diseases, announced today $40 million in Series C funding led by …See details»
Cerebral Therapeutics, Inc. Names Guy Anthony as Chief Financial ...
Aug 3, 2021 John Foster President & Chief Operating Officer P: 303-347-5448 E: info@cerebraltherapeutics.com Release Summary Cerebral Therapeutics, Inc. Names Guy …See details»
Cerebral Therapeutics, Inc. Secures $40 Million Series C Financing
Jun 28, 2022 Proceeds support late-stage clinical program in medically refractory epilepsy and intracerebroventricular therapies pipeline AURORA, Colo., June 28, 2022 — Cerebral …See details»
Cerebral Therapeutics Announces Enrollment of First Patient in a ...
Nov 17, 2020 For more information, visit www.cerebraltherapeutics.com. About The Study. The Phase 2b, randomized, placebo-controlled, double-blind study is designed to expand on …See details»
Cerebral Therapeutics Raises $40M in Series C Financing
Jun 28, 2022 Cerebral Therapeutics, an Aurora, CO-based clinical-stage pharmaceutical company, raised $40M in Series C funding.. The round was led by Lynx1 Capital Management …See details»
Cerebral Therapeutics Raises Series A Extension Financing to …
Mar 8, 2019 For more information please visit www.cerebraltherapeutics.com. For Investors & Media: William Poncy 951-204-2229 [email protected] SOURCE Cerebral Therapeutics. …See details»
Cerebral Therapeutics™ to Present Clinical Data at Antiepileptic …
May 16, 2019 For more information, please visit www.cerebraltherapeutics.com. For Investors: Tiberend Strategic Advisors, Inc. Tirth Patel 212-375-2694 [email protected] SOURCE …See details»
Cerebral Therapeutics Completes $35 Million Series B Financing
Jan 7, 2020 For more information please visit www.cerebraltherapeutics.com. Contact Tiberend Strategic Advisors, Inc. Miriam Weber Miller 212-375-2694 [email protected] SOURCE …See details»